<DOC>
	<DOCNO>NCT00002768</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation follow chemotherapy treat patient acute myeloid leukemia second remission .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Acute Myeloid Leukemia Second Remission</brief_title>
	<detailed_description>OBJECTIVES : I . Determine ability mobilization use cytarabine , etoposide , filgrastim ( G-CSF ) , condition use busulfan etoposide , autologous peripheral blood stem cell transplantation generate 2-year disease-free survival rate least 30 % patient acute myeloid leukemia ( AML ) second complete remission . II . Determine whether treatment-related mortality limit less 20 % patient treated regimen . III . Determine whether adequate number PBSC collect patient . IV . Determine engraftment kinetics prim PBSC obtain patient . OUTLINE : Mobilization/harvest : Patients receive cytarabine IV 2 hour every 12 hour etoposide IV continuously day 1-4 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) begin day 14 continue peripheral blood stem cell ( PBSC ) harvest . When blood count recover , PBSC harvest select CD34+ cell . Conditioning : Beginning least 4 week hospital discharge mobilization harvest blood count recover , patient receive oral busulfan every 6 hour day -7 -4 etoposide IV 4 hour day -3 . PBSC reinfused day 0 . G-CSF administer SC begin day 0 continue blood count recover . Patients document CNS disease first relapse receive methotrexate intrathecally interval 1 week great and/or PBSC transplantation total 6 dos . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 26-48 patient accrue within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) second complete remission ( CR ) 30 day less 1 year study entry Second CR define follow : Neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Normal bone marrow morphology excess blast ( great 5 % ) No myelodysplasia No extramedullary CNS leukemia Initial diagnosis de novo AML ( M0M7 ) No prior myelodysplasia No myeloproliferative disease No secondary AML Cytogenetics require No cytogenetic evidence persistent leukemia cytogenetics perform PATIENT CHARACTERISTICS : Age : 15 69 Hematopoietic : See Disease Characteristics Granulocyte count least 1,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST le 3 time normal Alkaline phosphatase less 3 time normal No cirrhosis chronic hepatitis Biopsy require chronic liver disease suspect ( history alcohol abuse possible hepatitis ) Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow/stem cell transplantation Chemotherapy : Prior nonablative chemotherapy initial diagnosis , initial remission , reinduction therapy ( produce current second remission ) allow At least 4 week since hospital discharge reinduction therapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior postremission therapy second remission</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>